Skip to main content
. 2025 Jul 1;51(6-7):249–269. doi: 10.14745/ccdr.v51i67a04

Table 2. Clostridioides difficile infection data, Canada, 2019–2023a.

C. difficile infection data Number of infections and incidence rates (per year)
2019 2020 2021 2022 2023
All cases
Number of C. difficile infection cases 3,600 3,650 3,640 3,878 4,453
Rate per 1,000 patient admissions 3.69 4.10 3.93 4.13 4.06
Rate per 10,000 patient days 4.90 5.35 5.07 4.97 5.05
Number of reporting hospitals 73 82 82 82 98
All-cause mortality rate
Number of deaths 63 54 66 64 74
All cause mortality rate per 100 cases (%)b 8.5 9 8.8 8.9 8.2
HA-CDI
Number of HA-CDI cases 2,662 2,625 2,571 2,819 3,142
Rate per 1,000 patient admissions 2.73 2.95 2.78 3.00 2.86
Rate per 10,000 patient days 3.62 3.85 3.58 3.62 3.56
Number of reporting hospitals 73 82 82 82 98
All-cause mortality rate
Number of deaths 47 39 50 54 58
All cause mortality rate per 100 cases (%)b 8.2 8.7 9.2 9.9 8.7
CA-CDI
Number of CA-CDI cases 938 1,025 1069 1,059 1,311
Rate per 1,000 patient admissions 1.17 1.38 1.38 1.35 1.42
Rate per 10,000 patient days 1.57 1.83 1.81 1.65 1.77
Number of reporting hospitals 62 71 71 71 87
All-cause mortality rate
Number of deaths 16 15 16 10 16
All cause mortality rate per 100 cases (%)b 9.4 9.6 7.4 5.8 6.3

Abbreviations: C. difficile, Clostridioides difficile; CA, community-associated; CDI, Clostridioides difficile infections; HA, healthcare-associated

a There was no resistance to tigecycline, vancomycin or metronidazole in C. difficile isolates submitted to the National Microbiology Laboratory 2019–2023

b Mortality data are collected during the two-month period (March and April of each year) for adults (aged 18 years and older) and year-round for children (aged one year to younger than 18 years old). Among paediatric patients, there was no death attributable to healthcare-associated C. difficile infection